RT Journal Article
SR Electronic
T1 Chemoradiation for primary invasive squamous carcinoma of the vagina
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 110
OP 117
DO 10.1136/ijgc-00009577-200401000-00015
VO 14
IS 1
A1 J. L. Dalrymple
A1 A. H. Russell
A1 S. W. Lee
A1 S. A. Scudder
A1 G. S. Leiserowitz
A1 W. K. Kinney
A1 L. H. Smith
YR 2004
UL http://ijgc.bmj.com/content/14/1/110.abstract
AB Objective To report outcomes for patients with primary, invasive, squamous carcinoma of the vagina treated with chemoradiation.Methods Between 1986 and 1996, 14 patients were treated with primary therapy consisting of synchronous radiation and chemotherapy. Patients were judged not to be surgical candidates based on tumor size, location, and concerns related to urinary, bowel, or sexual function. Three patients were FIGO stage I, ten patients stage II, and one patient stage III. Radiation consisted of teletherapy alone (six patients) or in combination with intravaginal brachytherapy (eight patients). Total radiation dose ranged from 5700 to 7080 cGy (median 6300 cGy). Chemotherapy consisted of 5-fluorouracil alone (seven patients), or with cisplatin (six patients) or mitomycin-C (one patient).Results One patient failed locally at 7 months and died of disease at 11 months. Four patients died of intercurrent illness (46, 92, 104, 109 months) and nine are alive and cancer-free 74–168 months after treatment (median 100 months). There were no vesicovaginal or enterovaginal fistulae.Conclusions Radiation with synchronous chemotherapy is an effective treatment for squamous carcinoma of the vagina. Cancer control outcomes compare favorably with previously published results employing higher dose radiation as monotherapy.